Best payment processor for telemed semaglutide and compounding operators

Telemedicine GLP-1 prescribing paired with 503A/503B compounding pharmacies has been the breakout DTC vertical of 2024-26. Payment underwriting for these operators has not caught up to the business model, and 2025 FDA actions are actively changing what is legal. This is one of the verticals where processor selection is as important as product-market fit.

1. The legal backdrop

FDA declared semaglutide off the shortage list in early 2025 and tirzepatide off in late 2024. Under Federal law, compounded versions of drugs that are not on the shortage list may only be made for individualized patient needs (not mass production). Many telemed operators are in regulatory gray zone. Processors follow the legal framing closely.

2. Who approves (as of 2026)

The approval pool narrowed significantly in 2025. Current bench:

• Specialty high-risk: Durango, PaymentCloud, Soar — all selective, each will require detailed compliance documentation.
• Healthcare-ISO specialists: CompuMed, Spring Health Payments, a few ISOs with Esquire Bank or Evolve relationships.
• Direct acquirer: Some operators with $5M+/month have negotiated direct with Chase Paymentech or First American — case by case.

Mainstream (Stripe, Square, Shopify, PayPal) all prohibit prescription medication DTC.

3. Rate benchmarks

For a $2M/month telemed GLP-1 operator:

Specialty high-risk placement: 4.5-5.9% effective, $200-500 monthly, 10-20% rolling reserve 180 days, $995-2,500 setup.

Healthcare-specialist placement: 3.95-4.95% effective, 8-12% reserve, deeper underwriting diligence.

Direct acquirer (rare, enterprise scale): 3.25-3.95% effective, 5-8% reserve, dedicated compliance review.

4. Compliance documentation required

DEA registration if applicable. State pharmacy licenses for every state shipped. 503A registration (traditional compounding) or 503B registration (outsourcing facility). USP 797/795/800 compliance documentation. Telemed provider licenses for every state where consultations occur. Patient-specific prescription workflow documentation. This pack is non-negotiable; missing pieces disqualify applications.

5. Chargeback profile

GLP-1 compounding chargebacks run 0.4-0.9%. Friendly fraud ("I didn't order this") and customer-initiated cancellations make up most disputes. Clear consent documentation + descriptor that customers recognize + 24-hour support response window keeps ratio under 0.7%.

6. Subscription model considerations

Most telemed GLP-1 is subscription (monthly dose shipments). First-charge chargebacks manageable. Rebill chargebacks depend on the customer service quality and the ease-of-cancellation path. Pharmacies with opaque cancellation processes see 2-4x the chargeback rate of operators with one-click cancellation.

7. FDA action risk

The 2025 FDA framework can eliminate compounded GLP-1 legality for mass production. Operators whose entire business is compounded GLP-1 need rail diversification and business model contingency — not just payment diversification. If FDA tightens enforcement, the category exits payments entirely.

8. Patient-specific compounding workflow

To remain legal post-shortage, compounding must be patient-specific — individualized dosing or formulation based on documented patient need. "Standard 2.5mg/week" is not patient-specific. "Compounded with B12 for nausea mitigation per Dr. X prescription" is patient-specific. Processor compliance audits check for this documentation.

9. State licensing complexity

50-state telemed requires 50 state telemed registrations or medical board reciprocity agreements. 50-state pharmacy shipping requires 50 state pharmacy licenses or NABP Verified Pharmacy Practice Sites (VPPS) accreditation. Operators missing state licenses eventually get flagged by state boards, then by processors.

10. Multi-MID strategy

Enterprise telemed GLP-1 operators run 2-3 MIDs across different acquirers to survive policy changes. Orchestration routes by BIN and product line. See multi-brand playbook.

11. Alternative rails

Some operators offer ACH via Plaid as a primary rail — lower fees, lower chargeback risk, worse conversion. HSA/FSA support through Truemed or similar can expand payment options. Crypto has been explored but adds reconciliation and reporting complexity.

12. What to do if the vertical tightens

Operators who build only on compounded GLP-1 should be planning for FDA-enforcement scenario now. Pivots include: branded GLP-1 via legitimate telemed referral, alternative peptide categories (with their own underwriting), weight loss coaching with non-GLP-1 prescriptions, or exit. Payment infrastructure follows the regulatory reality.

Application pack for specialty approval

• State pharmacy and telemed licenses (all states served).
• 503A or 503B registration.
• USP 795/797/800 documentation.
• Provider credentialing and insurance.
• Patient-specific prescribing workflow documentation.
• 6 months of processing statements (if previously live).
• Detailed product mix and expected volume.
• Customer service and cancellation SOP.

Where to start

If you are under $500k/month, start with Durango or PaymentCloud through a healthcare-specialty rep. If you are $1M+/month, add a healthcare-ISO placement for diversification. At $5M+/month, consider direct acquirer conversations. See telemed hormone therapy, telemed compounding rates, or apply for a placement fit check.

13. Outsourcing facility (503B) versus traditional (503A) treatment

503B outsourcing facilities register with FDA and can produce in larger batches but face more stringent cGMP. Payment underwriting is slightly friendlier because the facility is federally registered. 503A traditional compounding is patient-specific but has less federal visibility. Processors sometimes distinguish; make sure your application is accurate.

14. Patient consent and informed use

Telemed consultation that results in compounded prescription needs documented informed consent — patient acknowledges receipt of compounded (not FDA-approved) medication, understands risks, consents. Consent audit trail is frequently reviewed by processors during compliance audits. Missing consent = MID risk.

15. Insurance billing and HSA integration

GLP-1 compounding for weight loss is rarely covered by insurance. HSA/FSA coverage depends on letter of medical necessity. Truemed integration lets eligible patients pay with HSA/FSA dollars. Adds conversion on some segments; does not replace primary payment rail.

16. What happens when FDA acts

If FDA enforces harder on compounded GLP-1, timeline to action: warning letters first, followed by state board action (6-12 months typical), followed by federal civil action. During that window operators should stand up alternative verticals or transition to referring patients to branded GLP-1 via telemed.